Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ImmuCell Corporation reported revenue of $28M, up 4.3% year over year. Operating margin was 6.0% and net margin -3.8%, on a free-cash-flow margin of 4.4% with capital expenditure at 4.5% of revenue. Every figure is computed directly from ICCC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $28M | 6.0% | -3.8% |
| FY2024 | $26M | -6.2% | -8.1% |
| FY2023 | $17M | -32.9% | -33.1% |
| FY2022 | $19M | -12.4% | -13.4% |
| FY2021 | $19M | 1.3% | -0.4% |
How does ICCC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.